Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
Send Cancel

VMD urged to overturn decision on flunixin
Flunixin is a common analgesic used in horses with colic

Product suspended over potential risk to humans

Leading equine veterinary association BEVA is urging the Veterinary Medicines Directorate (VMD) to overturn its decision to suspend the sale of flunixin.

Flunixin is a common analgesic used in horses with colic, as well as for those undergoing surgery and other conditions. On Thursday (26 July), the VMD suspended the product after the Committee for Medicinal Products for Veterinary Use (CVMP) said that a solvent in the injectable formulation - diethanolamine - could pose a risk to humans.

Now BEVA is calling on the VMD to overturn this decision in horses not destined for the human food chain, to reduce the potential impact on equine welfare. It argues that the decision had been made without warning or consultation with the veterinary profession.

“BEVA is fully supportive of all attempts to promote food safety, however, flunixin is widely viewed as the gold-standard painkiller in horses and is commonly used in horses undergoing both elective and emergency surgery, for the crippling pain associated with laminitis and for severe forms of colic,” said BEVA president Jonathan Pycock.

“BEVA is calling on the VMD to immediately enable limited batch release of flunixin for use in horses not destined for the human food chain in the interests of animal welfare. The equine veterinary profession has always been open to consultation with the VMD on a range of important matters relating to responsible medicine use, antibiotic resistance, horse identification, passports and the horse meat issue.

“BEVA is perplexed as to why the VMD failed to consult with the equine veterinary industry on the animal welfare impact of withdrawing such an important drug.”

Used widely throughout the veterinary industry, flunixin is the only medicine licensed for the treatment of sepsis. BEVA states that no recall notices have been issued and therefore veterinary surgeons may continue to prescribe medicines that are in stock.

A disruption to the supply chain, however, could lead to shortages of this medicine in clinical practic, it said. 

Image (C) Redwings Horse Sanctuary

Become a member or log in to add this story to your CPD history

ISFM announces first veterinary nurse conference

News Story 1
 The International Society of Feline Medicine (ISFM) - the veterinary division of International Cat Care - has announced its first annual conference dedicated to veterinary nurses. The day offers an opportunity to meet up with colleagues and enjoy more than five hours of stimulating CPD.

The conference is being held at the Crowne Plaza Hotel, Stratford-Upon-Avon, on Saturday 15 September 2018. Tickets are £95 per person and include lunch, coffee breaks, downloadable proceedings and CPD certificate. For details and to book your place visit  

Click here for more...
News Shorts
WSAVA awards Australian vet with 'Next Generation’ award

Australian vet Dr Guyan Weerasinghe has been crowned winner of the WSAVA ‘Next Generation’ Veterinary Award. The award recognises those who graduated within the last 10 years and have made a significant contribution to the welfare of companion animals and the veterinary profession as a whole.

Besides maintaining a small animal caseload, Dr Weerasinghe works for the Queensland Government’s Department of Agriculture where he is involved with animal disease surveillance and increasing the public health risks in veterinary practice. He also collaborates on various One Health projects across Australia and gives regular talks on the impact of climate change on animal health and welfare.

Dr Weerasinghe will receive his award at the WSAVA World Congress 2018 (25-28 September).